A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. in U.S. federal court, alleging violations of the Securities Exchange Act of 1934. The suit claims the company made false or misleading statements during the period from Aug. 3, 2023 to Dec. 26, 2025 about its understanding of the effects of a drug candidate for Osteogenesis Imperfecta, and that the truth emerged after the Phase III ORBIT study failed to show a statistically significant reduction in annualized fracture rate. Investors who purchased shares during the period may seek to participate, with a lead plaintiff deadline of April 6, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602201237PRIMZONEFULLFEED9658474) on February 20, 2026, and is solely responsible for the information contained therein.